vlog

Tor Savidge

Savidge

Tor Savidge, Ph.D.

Professor

Positions

Professor
Department of Pathology & Immunology
vlog of Medicine
Houston, TX, US

Professional Statement

My laboratory is actively researching Clostridium difficile pathogenesis and we were the first to identify toxin B as the major virulence factor in human intestine. We also identified a novel innate host defense mechanism against microbial toxin and pioneered new therapeutic concepts which we termed “allosteric therapeutics”.

My research has also played a central role in discovering novel glial cell functions in the gut.

Selected Publications

  • Savidge TC, Urvil P, Oezguen N, Ali K, Choudhury A, Acharya V, Pinchuk I, Torres AG, English RD, Wiktorowicz JE, Loeffelholz M, Kumar R, Shi L, Nie W, Braun W, Herman B, Hausladen A, Feng H, Stamler JS, Pothoulakis C. " " Nat. Med.. 2011 Sep ; 17 (9) : 1136-41.
    Pubmed PMID: .
  • Chen D, Savidge T.. " " Science. 2015 Aug 28; 349 (6251) : 936.
    Pubmed PMID: .
  • Chen D, Oezguen N, Urvil P, Ferguson C, Dann SM, Savidge TC.. " " Sci Adv. 2016 Mar 25; 2 (3)
    Pubmed PMID: .
  • Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, Johnson MH, Sofroniew MV. " " Cell. 1998 Apr 17; 93 (2) : 189-201.
    Pubmed PMID: .

Funding

Allosteric therapy of the Clostridium difficile toxins
#R01 NIAID AI10094001
(05/01/2012 - 05/31/2017)
Grant funding from NIH R01
The goal of this study is to develop novel allosteric inhibitors for the C. difficile toxins using inositolphosphate analogs and S-nitrosothiol biology.
Metabolome-Based Biomarkers and Neutraceuticals in Clostridium Difficile Infection.
#R21DK096323-01
(09/15/2014 - 08/31/2015)
Grant funding from NIH R21
The goal of this study is to develop validate metabolomics biomarkers of disease susceptibility to Clostridium difficile.

Skills

Expert Omics review
NASA Human Research Roadmap for 2035 Mission to Mars.
Editorial Board
American Journal of Physiology (Gastroenterology & Hepatology).

to edit your profile